Cervomed Inc. cash flow statement
In fiscal 2025, Cervomed Inc.'s operations generated −$23.4m of cash; it spent $0 on capital projects, leaving free cash flow of −$23.4m.
Cash flow statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −2 | −12 | −4 | −1 | −3 | −7 | −17 | −23 | −28 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | — | — | — | — |
| Stock-based pay | — | — | — | 2 | 0 | 0 | 1 | 1 | 1 |
| Capital spending | 0 | 0 | — | — | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −2 | −12 | — | — | −3 | −7 | −17 | −23 | −28 |
| Free cash flow after stock pay | — | — | — | — | −3 | −8 | −18 | −25 | −29 |
| Shares issued | 2 | 4 | 0 | 0 | 0 | 1 | 46 | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −4,855 | −8,051 | −3,894 | −6,515 | −6,465 | −6,576 | −8,018 | −6,918 |
| Stock-based pay | 271 | 338 | 361 | 497 | 292 | 299 | 349 | 362 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −4,855 | −8,051 | −3,894 | −6,515 | −6,465 | −6,576 | −8,018 | −6,918 |
| Free cash flow after stock pay | −5,126 | −8,389 | −4,256 | −7,012 | −6,757 | −6,874 | −8,368 | −7,281 |
| Shares issued | −13 | 0 | — | — | — | — | — | — |
Compare with peers
- Cardiff Oncology, Inc. cash flow
- Clene Inc. cash flow
- Celldex Therapeutics, Inc. cash flow
- Medicinova Inc cash flow
- Shattuck Labs, Inc. cash flow
Head to head: CRDF vs CRVOCLNN vs CRVOCLDX vs CRVO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies